Anita Brikman: Expanding Access to Plasma-Derived Medicines in India
Anita Brikman, President and CEO of the Plasma Protein Therapeutics Association (PPTA), shared on LinkedIn:
”Returning from India on behalf of Plasma Protein Therapeutics Association (PPTA), I look back at an incredibly meaningful- even transformative- journey.
Our time there was centered on listening, learning and strengthening partnerships across a rapidly evolving healthcare ecosystem.
From conversations with regulators and public health leaders to time spent with clinicians, patient advocates, and scientists, it’s clear that progress in expanding access to plasma-derived medicines could be deeply impactful.
I was especially moved by the dedication of individuals who have turned personal experience into advocacy.
Their efforts are helping to build momentum toward a future where more patients with rare and chronic conditions can receive timely and effective treatment with plasma-derived medicines.
While there is still much to be done, the growing collaboration across India signals real opportunity in expanding access to care across the region.
Thank you to the many partners who welcomed us, shared their insights, and continue to push this work forward.
It’s an honor to be part of the life-enabling power of plasma.”
Stay updated with Hemostasis Today.
-
Mar 27, 2026, 16:26Robert Talac: Platelet Concentration Gap – PRP vs Advanced PRF
-
Mar 27, 2026, 16:23Nathan Wong: Lp(a) Testing as a Class I Recommendation in 2026 Guidelines
-
Mar 27, 2026, 16:21Jeff Sternlicht: Inflammation is The ‘Storm’ Before Atherosclerosis
-
Mar 27, 2026, 16:19Laura Baglow-Micic: Register for the Transfusion Research Network for The SWiFT Trial Results Webinar
-
Mar 27, 2026, 16:18Chris Hannay: Rising Demand for Immunoglobulin Driving Plasma Industry Growth in Canada
-
Mar 27, 2026, 15:33Caitlin Raymond: A Manifesto on Three Foundational Values for a Real Culture of Wellness
-
Mar 27, 2026, 15:30Shankar Biswas: Impact of Coronary Collaterals on Mortality in STEMI
-
Mar 27, 2026, 15:21Joseph Ebubechukwu: The Hidden Impact of Elevated PCV on Patient Wellbeing
-
Mar 27, 2026, 14:53Tooba Rehman: Extending Impella 5.5 Support Beyond 14 Days in Cardiogenic Shock